Meta-Analysis: Tirzepatide Improves Physical Function and Quality of Life in Adults With Overweight or Obesity | Research

The takeaway

A meta-analysis of 6 RCTs with 4,531 participants found that weekly tirzepatide (10 or 15 mg) significantly improved patient-reported physical function compared to placebo in adults with overweight or obesity.

SF-36 physical function improved by 2.26 points vs placebo
Across 4,531 participants in 6 RCTs, tirzepatide produced statistically significant improvements in patient-reported physical function at both 10 and 15 mg doses.

What the researchers found

Tirzepatide significantly improved physical function compared to placebo on both primary outcome measures: SF-36 physical function domain (MD 2.26 points; 95% CI 1.76-2.76) and IWQOL-Lite-CT physical function subscale. Both the 10 mg and 15 mg weekly doses showed consistent benefits in subgroup analyses.

However, between-study heterogeneity was extremely high (I² = 99.8%), which limits the interpretability of pooled estimates. The overall certainty of evidence was rated as moderate by GRADE criteria due to risk of bias and inconsistency across studies.

Why it matters

Obesity significantly impairs physical function and quality of life, but weight loss drugs are often evaluated only on weight and metabolic outcomes. This meta-analysis demonstrates that tirzepatide's benefits extend beyond the scale — patients actually feel and function better physically. This is important for justifying the clinical value and cost of these medications, as physical function directly impacts daily life, independence, and overall wellbeing.

How the study worked

Systematic review and meta-analysis of randomized controlled trials found through PubMed, Embase, and Cochrane Library searches up to July 2025. Included RCTs compared once-weekly tirzepatide (10 or 15 mg) with placebo and reported validated physical function outcomes. Random-effects models calculated pooled mean differences with 95% confidence intervals. Evidence quality was assessed using GRADE methodology.

What this study cannot tell us

The extremely high between-study heterogeneity (I² = 99.8%) is a major limitation that makes the pooled estimates difficult to interpret definitively. This variability may reflect differences in patient populations, comorbidities, or study designs across the 6 RCTs. The GRADE certainty was moderate due to risk of bias and inconsistency. Physical function was a secondary outcome in the original trials, not their primary endpoint.

How to read the evidence

This is a systematic review and meta-analysis of randomized controlled trials — among the highest levels of evidence. The GRADE assessment rated the certainty as moderate, reflecting concerns about risk of bias and the extremely high heterogeneity between studies. The evidence strongly suggests benefit but with some uncertainty about the precise magnitude.

When this study was published

Published in 2026 with searches through July 2025, this is the most current meta-analysis available on tirzepatide's physical function effects, incorporating the latest clinical trial data.

The bigger picture

This meta-analysis contributes to the growing evidence that GLP-1-based peptide therapies provide benefits well beyond weight loss and blood sugar control. Physical function improvement is a patient-centered outcome that resonates with regulators, insurers, and patients alike. As the field moves toward evaluating quality-of-life metrics alongside traditional clinical endpoints, studies like this strengthen the case for broader access to these medications.

Questions still open

What accounts for the extremely high heterogeneity between studies, and do specific patient subgroups show more consistent physical function improvement?
Does the physical function improvement persist after tirzepatide discontinuation, or does it reverse with weight regain?
How does tirzepatide's physical function benefit compare to that achieved by exercise interventions or bariatric surgery?

Common questions

Does tirzepatide actually make people more physically capable, or do they just feel better?

This meta-analysis measured patient-reported physical function — how well people feel they can perform daily physical activities. While it doesn't measure objective physical performance (like timed walking tests), the validated questionnaires used (SF-36 and IWQOL-Lite-CT) are well-established tools that capture meaningful changes in how people experience their physical abilities in everyday life.

Is the physical function improvement from tirzepatide clinically meaningful?

The 2.26-point improvement on the SF-36 physical function scale is statistically significant, though clinical meaningfulness depends on context. For individuals with obesity-related physical limitations, even modest improvements in physical function can translate to meaningful gains in daily activities like walking, climbing stairs, and carrying groceries. The consistent benefit across both dose groups adds confidence to the finding.

Read the original research

Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis.

Diabetes, obesity & metabolism

View on PubMed ↗Publisher’s paper ↗

Citation

Schmidt, Pedro Henrique Siedschlag; de Souza, Vitor Sodré Nonato; Machado, Luís Guilherme; Rodrigues, João Vitor Ahlf; da Cruz, João Victor Ramos; de Souza, Lis Sodré Nonato; Dos Santos, Bruno Eulálio; Hohl, Alexandre; Ronsoni, Marcelo Fernando; van de Sande-Lee, Simone. (2026). Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.70529